Login to Your Account

Seattle Genetics Gets $118.2M for Antibody Conjugate, More

By Donna Young

Thursday, August 13, 2009
In the wake of a stock bump following a $2.4 billion acquisition offer for fellow antibody firm Medarex Inc., Seattle Genetics Inc. is boosting its cash position by $118.2 million through a public stock offering. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription